ENTRY       D06565                      Drug
NAME        Galsulfase (USAN/INN);
            Galsulfase (genetical recombination) (JAN);
            Aryplase (TN)
PRODUCT     NAGLAZYME (BioMarin Pharmaceutical)
FORMULA     C2529H3843N689O716S16
EXACT_MASS  55833.1016
MOL_WEIGHT  55867.8004
SEQUENCE    AGASRPPHLV FLLADDLGWN DVGFHGSRIR TPHLDALAAG GVLLDNYYTQ PLCTPSRSQL
            LTGRYQIRTG LQHQIIWPCQ PSCVPLDEKL LPQLLKEAGY TTHMVGKWHL GMYRKECLPT
            RRGFDTYFGY LLGSEDYYSH ERCTLIDALN VTRCALDFRD GEEVATGYKN MYSTNIFTKR
            AIALITNHPP EKPLFLYLAL QSVHEPLQVP EEYLKPYDFI QDKNRHHYAG MVSLMDEAVG
            NVTAALKSSG LWNNTVFIFS TDNGGQTLAG GNNWPLRGRK WSLWEGGVRG VGFVASPLLK
            QKGVKNRELI HISDWLPTLV KLARGHTNGT KPLDGFDVWK TISEGSPSPR IELLHNIDPN
            FVDSSPCPRN SMAPAKDDSS LPEYSAFNTS VHAAIRHGNW KLLTGYPGCG YWFPPPSQYN
            VSEIPSSDPP TKTLWLFDID RDPEERHDLS REYPHIVTKL LSRLQFYHKH SVPVYFPAQD
            PRCDPKATGV WGPWM
  TYPE      Peptide
REMARK      Therapeutic category: 3959
            ATC code: A16AB08
            Product: D06565<JP/US>
EFFICACY    Lysosomal storage disease treatment, Enzyme replacement (arylsulfatase B)
  DISEASE   Mucopolysaccharidosis VI; Maroteaux-Lamy syndrome [DS:H00131]
  TYPE      Enzyme replacement therapy product
TARGET      ARSB* [HSA_VAR:411v1] [HSA:411] [KO:K01135]
  PATHWAY   hsa00531(411)  Glycosaminoglycan degradation
            hsa04142(411)  Lysosome
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
               A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
                A16AB Enzymes
                 A16AB08 Galsulfase
                  D06565  Galsulfase (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Galsulfase
               D06565  Galsulfase (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               395  Enzyme preparations
                3959  Others
                 D06565  Galsulfase (USAN/INN); Galsulfase (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Sulfatases
                ARSB* [HSA_VAR:411v1]
                 D06565  Galsulfase (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D06565
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D06565
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D06565
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D06565
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D06565
DBLINKS     CAS: 552858-79-4
            PubChem: 47208221
///
